Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

14 Customer Reviews

  • Tumor growth of 827 GSC-derived xenografts treated with an AKT inhibitor perifosine (30 mg/kg body weight). Twenty-three days after tumor implantation in mice, perifosine was administered by intraperitoneal injection (daily for 5 days). Error bars represent SD. Five mice per group, *p < 0.01.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    Immunoblot analysis of pY-STAT3, EZH2, AKT, and trimethylated H3K27 in lysates from xenograft tumors treated with an AKT inhibitor perifosine.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • Co-IP analysis of methylated STAT3 in GBM xenograft tumors treated with perifosine.AKT inhibition in vivo decreased STAT3 methylation and pY-STAT3, but increased global levels of H3K27 trimethylation.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    IF staining of pS21 EZH2 and pY-STAT3 on the frozen sections of GBM xenografts treated with vehicle or perifosine. Nuclei were stained with DAPI. Bar represents 10 microns.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • NRP-152 cells were transfected with Id1-luciferase reporter element as described in the figure and then incubated with±perifosine (10 nmol/L)  for 2 hours, followed by±LR3-IGF-I (10 nmol/L) for 24 hours. Cells were then treated with ±BMP4 and assayed for luciferase 2 hours later.

     

     

    Cancer Res 2010 70, 9106-9117. Perifosine (KRX-0401) purchased from Selleck.

     

    LAT2 is degraded by proteasomes after treatment with alkylphospholipids. A, 3-h treatment of NB4 cells before exposure to the proteasome inhibitor MG132 (10 μM) prevented the reduction of LAT2 induced by 25 μM ODPC. B, C, a similar effect was observed after exposure (30 min) of NB4 cells to the proteasome inhibitor MLN9708 (5 μM) followed by treatment with 25 μM ODPC (B) or 25 μM perifosine (C).

    Mol Cell Proteomics 2012 11(12), 1898-1912 . Perifosine (KRX-0401) purchased from Selleck.

  • Alkylphospholipid-induced morphological changes in HepG2 cells. Cell morphology was examined with an inverted microscope(20× original magnification). The morphology of HepG2 cells incubated with MEM/10% FBS is shown in the absence of any addition (control, A), or in the presence of 25 μM of HePC (B), edelfosine (C), ErPC (D) or perifosine (E) for 24 h. ErPC, erucylphosphocholine; FBS, fetal bovine serum; HePC, hexadecylphosphocholine; MEM, minimal essential medium.

     

     

    Brit J Pharmacol 2010 160, 355–366. Perifosine (KRX-0401) purchased from Selleck.

    Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting analysis demonstrating Ser473p-Akt and total Akt levels in HepG2 cells and Bel-7402 cells treated with increasing concentrations of perifosine for 24 h. Betaactin served as loading control. Bands were analyzed by Glyco Band-Scan software. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05,** P<0.01 vs. control, Student,s t test

     

     

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    Induction of apoptosis in hepatoma cells by treatment for 48 h with 10 μM perifosine. The treated cells were stained with DAPI and the apoptotic morphological changes in the nuclear chromatin were observed under a fluorescent microscope.

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting assay showing cleavage of caspase-3, caspase-9 and PARP in response to perifosine treatment in hepatoma cells. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05, ** P<0.01 vs. control, Student,s t test

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    This chart showed the change of the stable transfection cells in centrosome separation after the cells were treated with perifosine(1 μM)  6 hours, 12 hours and 24 hours. "C" means the control group, and "P" means the group treated with perifosine

    2010 Zhao Jing PHD Medical College of Peking University. Perifosine (KRX-0401) purchased from Selleck.

  • TEIF (telomerase transcriptional elements-interacting factor)gene is a novel human gene and cloned from the expression library of  HeLa cell through the hTERT promoter-based yeast one-hybrid assay. And now we are trying to find the interaction between TEIF and the EGF pathway.

     

     

    2010 Zhao Jing PHD Medical College of Peking University . Perifosine (KRX-0401) purchased from Selleck.

     After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Perifosine for 3h,followed by 15-minute  stimolation of 100ng/ml EGF.

     

     

     

    2010 Dr. Zhang of Tianjin Medical University. Perifosine (KRX-0401) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  MWLGeY5kfGmxbjDBd5NigQ>? NFXpeG4xNjVxMT:yMlUh|ryP NHHGNZY{KGh? NHWzbVVz\WS3Y3XzJJRp\SCkYYPhcEBESiC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVG2WmhiOjZyOUe4O|M>
T24 BC  MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV6wMlUwOS9{LkWg{txO NYPWZVJSOjRiaB?= M3jPWoVvcGGwY3XzJJNwemGoZX7pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHTlZ5Jm[XOn MXqyOlA6Pzh5Mx?=
T24 BC  NInWbGpCeG:ydH;zbZMhSXO|c3H5 M3m5UlIvPSEQvF2= M{CyN|I1KGh? M1izV5NmdnOrdHn6[ZMhSkNiY3XscJMhfG9ic3;yZYZmdmmkLXnu[JVk\WRiYYDvdJRwfGmlwrC= MWKyOlA6Pzh5Mx?=
HepG2 MVzGeY5kfGmxbjDBd5NigQ>? M3u2PFIxyqEQvF2= MV6yOOKhcA>? MYPwdo9lfWOnczDhckBqdnSnboPlJIN6fG:ybHHzcYlkKH[jY4XvcIl7[XSrb36gZ49zemW|cH;u[Ilv\yC2bzDhJI5wfGGkbHWg[Ilt[XSjdHnvckBw\iC2aHWgSXIh[2m|dHXycpM> NV\rbnVbOjV7M{SyN|I>
U-87 MG  Mk\LSpVv[3Srb36gRZN{[Xl? NGXUTJYzOMLizszN NXXYc4VVOjUEoHi= NGDUfZhqdmO{ZXHz[ZMh\G:3YnzlMY1mdWK{YX7lJIJwfW6mIIP0dpVkfHW{ZYO= NGjPc5MzPTl|NEKzNi=>
HepG2 NHPRVnpHfW6ldHnvckBCe3OjeR?= M2D4WlIxyqEQvF2= NUK4UYVwPi9{NDDo MnLkbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS MWSyOVk{PDJ|Mh?=
U-87 MG  NVPz[G1QTnWwY4Tpc44hSXO|YYm= NX\KblBDOjEEoN88US=> NUnJXHBLPi9{NDDo NWSyNI5RcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gUGM{NUmLIHPveJJm[XSnZDD3bZRpKEOT NYrpWXM2OjV7M{SyN|I>
HepG2 NUfnT5JDTnWwY4Tpc44hSXO|YYm= MmewNlDDqM7:TR?= NYHWN4VkPi9{NDDo MVzk[YNz\WG|ZYOgUGM{NUmLIHTl[5Ji\GG2aX;uxsBnem:vIE[gbC=> M{DsWlI2QTN2MkOy
U-87 MG  NUDxSXdoTnWwY4Tpc44hSXO|YYm= MXSyNOKh|ryP Mmf0Ok8zPCCq NH2yfJFqdmO{ZXHz[ZMhfGinIHH1eI9xcGGpaXOg[ox2gCBiYYSgOkBpKHeqaXzlJIlvcGmkaYTzJJRpcXNiZnz1fEBifCB{NHi= M4XnS|I2QTN2MkOy
HepG2 MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jWZ|IxNzRyIN88US=> MXOyOE81QCCq M4TQcolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MmLWNlU6OzR{M{K=
U-87 MG  M3vXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonrNlAwPDBizszN NH33TJczPC92ODDo MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MnLRNlU6OzR{M{K=
A549 M1P0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH71eJoxNjNvMUCg{txO M3\BTVI1Nzd{IHi= NFnqb|BqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXfrfnl3OjV4OUe4PVk>
H460 NYHIVHM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVntbI1wOC5|LUGwJO69VQ>? M136Z|I1Nzd{IHi= NU\t[WZWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M1XTWVI2Pjl5OEm5
A549 NG\Pd2tCeG:ydH;zbZMhSXO|c3H5 NH71SogyNzNizszN M321RlQ5KGh? NI\nTG9qdmS3Y3XzJIFxd3C2b4Ppdy=> MV:yOVY6Pzh7OR?=
H460 MUTBdI9xfG:|aYOgRZN{e2G7 MVqxM|Mh|ryP M3Ty[VQ5KGh? MoDVbY5lfWOnczDhdI9xfG:|aYO= NXXse4lXOjV4OUe4PVk>
A549 M{\kfmZ2dmO2aX;uJGF{e2G7 NEnSR24{KM7:TR?= MXW4JIg> M{OzfIJtd2OtczDBT3Qh[WO2aY\heIlwdg>? NWPCWG1YOjV4OUe4PVk>
H460 MVjGeY5kfGmxbjDBd5NigQ>? M4TST|Mh|ryP NYDqU404QCCq NGPCfXJjdG:la4OgRWtVKGGldHn2ZZRqd25? MXmyOVY6Pzh7OR?=
A549 MYHGeY5kfGmxbjDBd5NigQ>? M3PjelMh|ryP MlnGPEBp NHjsPZBjdG:la4OgcXRQWkNzLDDhcoQhTVKNLV3BVGsh[WO2aY\heIlwdiClb33ibY5m\CC5aYToJG1GUy1zNkK= MUCyOVY6Pzh7OR?=
H460 MYLGeY5kfGmxbjDBd5NigQ>? MoDLN{DPxE1? MnvtPEBp NUT4WYlm[myxY3vzJI1VV1KFMTygZY5lKEWUSz3NRXBMKGGldHn2ZZRqd25iY3;tZolv\WRid3n0bEBOTUtvMU[y MWWyOVY6Pzh7OR?=
RMG1 MnHHR4VtdCCYaXHibYxqfHliQYPzZZk> NHnHc5QyNTNyIN88US=> MWq3NkBp NIKyW5dl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NFjlenczPTVzOUG0PC=>
RMG2 NUPu[WprS2WubDDWbYFjcWyrdImgRZN{[Xl? MX2xMVMxKM7:TR?= MWm3NkBp M{Xp[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NX71W4dbOjV3MUmxOFg>
KOC7C NVHNOVRMS2WubDDWbYFjcWyrdImgRZN{[Xl? NF7EOGMyNTNyIN88US=> Mn;ZO|IhcA>? MVTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXXnfFNpOjV3MUmxOFg>
HAC2 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1rm[FEuOzBizszN M1fVOVczKGh? NV\4NpNr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MlTMNlU2OTlzNEi=
RMG2 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Ml;rNU0{OCEQvF2= M2TYVFQ5KGh? MWPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWTJUlRJOjV3MUmxOFg>
OVISE Mnv5R4VtdCCYaXHibYxqfHliQYPzZZk> NGnYUJgyNTNyIN88US=> NHTFSJg1QCCq MU\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NIjM[mozPTVzOUG0PC=>
SKOV3 MmPnR4VtdCCYaXHibYxqfHliQYPzZZk> M3O2bFEuOzBizszN NHj0Vo41QCCq M2rSXYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MlHNNlU2OTlzNEi=
A2780 MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXqw[HhMOS1|MDFOwG0> NI\lO5o1QCCq NYS3VlYy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M3T4bVI2PTF7MUS4
RMG1 MUjBdI9xfG:|aYOgRZN{e2G7 M1\5cFMxKM7:TR?= M3m2flI1KGh? MljIbY5lfWOnczDhdI9xfG:|aYO= M{P4TFI2PTF7MUS4
RMG2 M3rhRmFxd3C2b4Ppd{BCe3O|YYm= NFe0XYs{OCEQvF2= M1rHOlI1KGh? MVrpcoR2[2W|IHHwc5B1d3Orcx?= M1\vZlI2PTF7MUS4
HCC1806 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPCfXYxNTFyIN88US=> NHjaVHg1QCCq NFX4N29GSzVyPUKuPFTjiIoEsfMAjVAvODdizszN M4DV[FI2Ojl|NUe2
MDA-MB-231  M2PxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKwMVExKM7:TR?= MUO0PEBp NVnmNZRsTUN3ME2xMlE{6oDLwsJihKkxNjB5IN88US=> MUGyOVI6OzV5Nh?=
GL-1 M{O5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe0NE4y6oDVMUCw5qCK|ryP MVO0PEBp MVLJR|UxRTlwOUGg{txO MlPDNlQ5QDF3MEi=
CLBL-1 NIHI[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2wMlHjiJNzMEFihKnPxE1? MlTXOFghcA>? NHHURm9KSzVyPUOzMlAh|ryP MmTSNlQ5QDF3MEi=
UL-1 M4LZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnTO2wxNjIkgKOxNFDjiIoQvF2= MVO0PEBp NHPsVm5KSzVyPUeuNFEh|ryP M1TyN|I1QDhzNUC4
Ema NHThdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TtOVAvOeLCk{GwNQKBkc7:TR?= M12xUlQ5KGh? NV[wUIY{UUN3ME21PE44KM7:TR?= NFP2VnozPDh6MUWwPC=>
PANC-1 M4PXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e2TVAuOjVizszN NH;XUoM4OiCq M1PKfolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NGjDOJEzPDVzOUe1NS=>
MIA M17hNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofKNE0zPSEQvF2= M4fDfFczKGh? NEjpXJJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MkSwNlQ2OTl5NUG=
AsPC-1 NFvsXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHPNlQ1OC1{NTFOwG0> M2rlUVczKGh? NWq1W401cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MUiyOFUyQTd3MR?=
PANC-1 MlrMSpVv[3Srb36gRZN{[Xl? MoHFNE42KM7:TR?= M{XSZ|I1KGh? M{XwUIlvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb|EwOiCyaH;zdIhwenmuYYTpc47DqA>? M2joXVI1PTF7N{Wx
MIA NEXmS2FHfW6ldHnvckBCe3OjeR?= NYDIdWlQOC53IN88US=> MmfiNlQhcA>? MoDkbY5pcWKrdIOgRYt1NCCVNluxMEBidmRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvcuKh Mmm3NlQ2OTl5NUG=
AsPC-1 M{jMbmZ2dmO2aX;uJGF{e2G7 NFfLSnoxNjVizszN MnLLNlQhcA>? MYHpcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> NFjQUGUzPDVzOUe1NS=>
U87MG NU\U[JNwS2WubDDWbYFjcWyrdImgRZN{[Xl? M2TqVlAuOjVizszN MV6yOE06PiCq MYXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MnHSNlQxPjV3MkK=
SGC7901  NEfsfVJHfW6ldHnvckBCe3OjeR?= NYD3fFVOOC55NT:xNOKh|ryP NGTYb2w1QCCq MXnk[YNz\WG|ZYOgdE1Cc3RiKGPldkA1PzNrLDDwMWdUUzQQsjCoV4VzKDlrLDDhcoQhSy2PWVOgcIV3\Wy|wrC= NEjQ[WIzOzlzMkK0Oi=>
MGC803  M4DsdWZ2dmO2aX;uJGF{e2G7 MmfENE44PS9zMNMg{txO MmXVOFjDqGh? M3HtPIRm[3KnYYPld{BxNUGtdDCoV4VzKDR5MzmsJJAuT1ONM98yJEhU\XJiOTmsJIFv\CCFLV3ZR{Bt\X[nbIRCpC=> MlrLNlM6OTJ{NE[=
TykNu M2roVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPPTWM2OD1|LkWg{txO M136O|I{QDd5MEGy
TykNuR NIjqOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vs[mlEPTB;NT61JO69VQ>? MX[yN|g4PzBzMh?=
M41 Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7tV|NDUUN3ME2yOE44KM7:TR?= M1;TS|I{QDd5MEGy
M41R NFrLemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm5UlRKSzVyPUG5Mlgh|ryP NF\6O24zOzh5N{CxNi=>
OVCAR8 MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHSTWM2OD1|MT6xJO69VQ>? NELhOFQzOzh5N{CxNi=>
HeyA8 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPPPWVzUUN3ME2yOE4{KM7:TR?= MVGyN|g4PzBzMh?=
A2780CP MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\iTWM2OD15Lk[g{txO MXmyN|g4PzBzMh?=
OVCAR5 M4Wyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLkTWM2OD14Lkeg{txO NHLLUGEzOzh5N{CxNi=>
A2780S NUm2TY9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF2LkWg{txO M3PJWlI{QDd5MEGy
MCAS MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4SxSGlEPTB;MUKuOUDPxE1? NWr1OVZiOjN6N{ewNVI>
NCI-H727 NYTzPXdIS2WubDDWbYFjcWyrdImgRZN{[Xl? MX6wMVExOCEQvF2= MmTZNlQwPzJiaB?= MkHE[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NEfsUpEzOjR7OUSzOy=>
GOT1 Mn64R4VtdCCYaXHibYxqfHliQYPzZZk> M4C0OVAuOTByIN88US=> M2TvOlI1Nzd{IHi= MmDp[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NWDUdYh6OjJ2OUm0N|c>
BON1 MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUSwMVExOCEQvF2= MXKyOE84OiCq MonX[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NX7BXoR1OjJ2OUm0N|c>
BON1 NUPXe2Z4SXCxcITvd4l{KEG|c4PhfS=> NIDqNGYxNTFyIN88US=> NHvJTnkzPCCq MV3pcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 MWWyNlQ6QTR|Nx?=
BON1 MmTkSpVv[3Srb36gRZN{[Xl? NEPxe|U4NjVxMUCg{txO NYTmZVRvQCCq MY\k[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[geIhmKGGwdHmtZZBweHSxdHnjJJBzd3SnaX7zJGJEVDJiYX7kJGJkdC2[TB?= NWPYOnd6OjJ2OUm0N|c>
Kasumi-1 MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M17qZlAuOjBizszN NHjwcmUzPC92ODDo NEG1Uo9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NXLwdVdiOjJ2MEeyNlg>
HL-60 MoPmR4VtdCCYaXHibYxqfHliQYPzZZk> NV7kVJdVOC1{MDFOwG0> NEnwU2IzPC92ODDo M{DyVIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> M2mzV|IzPDB5MkK4
Kasumi-1 MoLoRZBweHSxc3nzJGF{e3OjeR?= NYHoRWYyOTBizszN MoXtNlQhcA>? NXe0OoZMcW6mdXPld{BieG:ydH;zbZM> NHLJNIUzOjRyN{KyPC=>
HL-60 M4HObGFxd3C2b4Ppd{BCe3O|YYm= MnG4NVAh|ryP MlrWNlQhcA>? NH;USZhqdmS3Y3XzJIFxd3C2b4Ppdy=> NHnMUXQzOjRyN{KyPC=>
Kasumi-1 NVjOb4g6TnWwY4Tpc44hSXO|YYm= MmrxNk42NzVxMUCg{txO MWGyOEBp MoTU[IVkemWjc3XzJGFsfCCjbnSgdE1Cc3RibHX2[Yx{yqCmb4PlMYRmeGWwZHXueIx6 NFPkSpgzOjRyN{KyPC=>
HL-60 Mnr2SpVv[3Srb36gRZN{[Xl? M3vNN|IvPS93L{GwJO69VQ>? MX[yOEBp M3:0fIRm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>? NVSzZYRxOjJ2MEeyNlg>
Kasumi-1 NWLHfZJHTnWwY4Tpc44hSXO|YYm= NIfDVFgzNjVxNT:xNEDPxE1? MkL2NlQhcA>? MU\pcoR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MWOyNlQxPzJ{OB?=
HL-60 MXvGeY5kfGmxbjDBd5NigQ>? MnvrNk42NzVxMUCg{txO NXLoN3RiOjRiaB?= NETYUHVqdmS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiSl7LNU8zKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M{DJeVIzPDB5MkK4
K562 M{S3dWZ2dmO2aX;uJGF{e2G7 MVuyNEDPxE1? Ml;sOFghcA>? M4n4Rolv\HWlZYOgZZV1d3CqYXf5xsA> MVGyNlQxPzJ{OB?=
OCUT1 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTENE4yNTNizszN NUjPeY9tPSCm MkjSbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NIHuSmgzOjB7MEK3NS=>
K1 M1T5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLxNE4yNTNizszN NGDXNmg2KGR? MkiwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MX:yNlA6ODJ5MR?=
OCUT1 MVvGeY5kfGmxbjDBd5NigQ>? MX[zJO69dQ>? M3z4XFI1KGh? NGfXOIdk[XW|ZYOgZUBlemGvYYTpZ{BqdmO{ZXHz[UBqdiCJMj;NJJBp[XOn MkPmNlIxQTB{N{G=
CaOV3 NF63O5hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mk\iNU82NzFyIN88US=> NYr3U2toPDhiaB?= M{DB[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6ncjDjc5Rz\WG2ZXSge4l1cCCyYXPsbZRigGWu MmLMNlE4PzVyNUS=
SKOV3 MYLDfZRwfG:6aXPpeJkhSXO|YYm= M3THVlUh|ryP MWW0PEBp NHrn[FFmdmijbnPld{Bx[WOuaYThfIVtKGmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh NXPLNlZ3OjF5N{WwOVQ>
A2780 NETsd3FEgXSxdH;4bYNqfHliQYPzZZk> MnXQOUDPxE1? MUe0PEBp NVH3PFRo\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? M3rWVVIyPzd3MEW0
HT-29  MoO1R5l1d3SxeHnjbZR6KEG|c3H5 M1OyeFUh|ryP M2LBXVQ5KGh? NUnMfXdM\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? Mnf4NlE4PzVyNUS=
A498 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHwNE01OCEQvF2= MXq3NkBp MXvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M4PGblIyPjR2MEWw
CAKI-1 M1jYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHJN201OC12MDFOwG0> M1TiVVczKGh? NITKOHJKSzVyfkGwJO69VQ>? NFv3ZZEzOTZ2NEC1NC=>
769-P NV\OPG4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYqxbXFVOC12MDFOwG0> MnX2O|IhcA>? MlP5TWM2OH53LUGwJO69VQ>? MkHINlE3PDRyNUC=
786-0 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX30NWp2OC12MDFOwG0> MXW3NkBp M2njeGlEPTC-NTFOwG0> MnfuNlE3PDRyNUC=
786-O Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLTVGhnOC1{MDFOwG0> M1rWNFczKGh? MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MWCyNVY1PDB3MB?=
CAKI-1 M1\LU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHHeJNuOC1{MDFOwG0> NF\oXG44OiCq M2PoWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M2TBWlIyPjR2MEWw
769-P MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3OzT|AuOjBizszN NUjjW5l6PzJiaB?= MorabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NVTCTZZ{OjF4NESwOVA>
A498 NFe5TIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn5WoNQOC1{MDFOwG0> M{PkS|czKGh? MWHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M3TTOVIyPjR2MEWw
CWR22RV1 NXfGcVhoS2WubDDWbYFjcWyrdImgRZN{[Xl? M2X4clExKM7:TR?= NHHDbWMzPCCq NHzGbnpqdmO{ZXHz[ZMhe2Wwc3n0bZZqfHlib3[gbJVu[W5iQ2fSNlJTXjFiY3XscJMhfG9icnHkbYF1cW:w MkDxNlE1QTZ{N{O=
CWR22RV1 NE\CSGdCeG:ydH;zbZMhSXO|c3H5 NXixclVxOTBizszN NHnK[WczPCCq NEDoOXRmdmijbnPld{Bz[WSrYYTpc44hcW6mdXPl[EBieG:ydH;zbZM> MWOyNVQ6PjJ5Mx?=
CWR22RV1 NH7kWodHfW6ldHnvckBCe3OjeR?= MoHZOUDPxE1? M{fVc|I1KGh? NVzCfVBqemWmdXPl[EBxcG:|cHjvdplt[XSrb36gc4YhSWu2IIPp[45q\mmlYX70cJk> MmnQNlE1QTZ{N{O=
HepG2  NEW1Z|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln1OU8yOC9{MD:0NEDPxE1? Mlv0NlQwPDhxN{KgbC=> NEKzXodqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NGjRXHozODh2MkSyOS=>
Bel-7402 M4\vWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XFXlUwOTBxMkCvOFAh|ryP Mn\ENlQwPDhxN{KgbC=> NEHxcXhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MWiyNFg1OjR{NR?=
HepG2  MVHGeY5kfGmxbjDBd5NigQ>? M4i2ZVUwOTBxMkCg{txO MkLuNlQhcA>? M4PFT5Jme3WudIOgbY4hfGinIHHjZ5VufWyjdHnvckBw\iClZXzsJI52dWKncjDpckB1cGViR{KvUUBxcGG|ZR?= NXvSXYRPOjB6NEK0NlU>
Bel-7402 MXPGeY5kfGmxbjDBd5NigQ>? NHL2T2I2NzFyL{KwJO69VQ>? NYWxTlU4OjRiaB?= MnrJdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn NEnWNXEzODh2MkSyOS=>
HepG2  M3X0W2Fxd3C2b4Ppd{BCe3O|YYm= M3\2dVUwOTBxMkCg{txO MXiyOE81QCCq NHfRO4VqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:|dYLl M1XnfFIxQDR{NEK1
Bel-7402 MnnaRZBweHSxc3nzJGF{e3OjeR?= M2fZOFUwOTBxMkCg{txO MYKyOE81QCCq NHLXTWpqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:|dYLl NFm0WZIzODh2MkSyOS=>
OAW-42 NFfp[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLPfWIxNTRyIN88US=> NX3sVVU4PzMEoHi= Ml;iTWM2OH5zMDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NVm3cpVJOjB2MEWyPVY>
PA-1  MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXUVWUxNTRyIN88US=> NGO5R5Q4OsLiaB?= MnLWTWM2OH5{NTFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NUDTc|ZVOjB2MEWyPVY>
SKOV3  M3LiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGwMVQxKM7:TR?= MlG3O|LDqGh? NI\Ub2pKSzVyfkOwJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MnPVNlA1ODV{OU[=
A2780 NXzDPFR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmxNE0zOCEQvF2= M2G4VFQ5Nzd{IHi= M1HKZmlEPTEEoE5CpFPDqM7:bR?= MUSyNFQxPTJ7Nh?=
A2780cis  MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqwMVIxKM7:TR?= M4TX[|Q5Nzd{IHi= MXnJR|UxyqB;wrC2xsDPxG1? M{jxdlIxPDB3Mkm2
SKW6.4 NY\ZTmVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HTSVIuOTEEoN88US=> NHjy[JU1QMLiaB?= MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MXSyNFE{ODl4MB?=
MAVER Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnsUYczNTFywrFOwG0> Mnf1OFjDqGh? M4Lu[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M{Xne|IxOTNyOU[w
BJAB M4TlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXDTIozNTFywrFOwG0> NH7uNmU1QMLiaB?= MYnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MYGyNFE{ODl4MB?=
OCI NHzxb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\YNk0yOMLizszN M3TZT|Q5yqCq Mo\0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NVvoOnhPOjBzM{C5OlA>
MOLM NYDJfnVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M125ZVIuOTEEoN88US=> M3\kWVQ5yqCq MoewbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MmHCNlAyOzB7NkC=
HL-60 NH\CUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PWe|IuOTEEoN88US=> NF7XfI81QMLiaB?= M{PKZolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NIjKNZEzODF|MEm2NC=>
SKW6.4 NGTVcmRCeG:ydH;zbZMhSXO|c3H5 MkDxNVDDqM7:TR?= MXeyOE81QCCq NEe5NYlqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 NHr5W4wzODF|MEm2NC=>
MAVER M3nybGFxd3C2b4Ppd{BCe3O|YYm= Mk\ENVDDqM7:TR?= MmjCNlQwPDhiaB?= NHTsW3lqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 MoP2NlAyOzB7NkC=
BJAB MUXBdI9xfG:|aYOgRZN{e2G7 NWiyfHhDOTEEoN88US=> NXL3NW5TOjRxNEigbC=> NEPxfFNqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 MVuyNFE{ODl4MB?=
OCI NF\QRVFCeG:ydH;zbZMhSXO|c3H5 MVexNOKh|ryP NYXUOXBMOjRxNEigbC=> MWrpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 NEnvVY0zODF|MEm2NC=>
MOLM NFWySJZCeG:ydH;zbZMhSXO|c3H5 NWrqToM6OTEEoN88US=> M{ixV|I1NzR6IHi= Mlq0bY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= MVOyNFE{ODl4MB?=
HL-60 M{KySWFxd3C2b4Ppd{BCe3O|YYm= NF\kfXYyOMLizszN NX7Xd5NQOjRxNEigbC=> NXj1d5VGcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> MmO3NlAyOzB7NkC=

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
in solvent
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02238496 Active, not recruiting Brain Tumor, Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01224730 Unknown status Cancer AEterna Zentaris January 2012 Phase 1
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01049841 Active, not recruiting Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01051557 Active, not recruiting Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm National Cancer Institute (NCI) January 2010 Phase 1|Phase 2
NCT01002248 Terminated Multiple Myeloma AEterna Zentaris|Dana-Farber Cancer Institute December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID